In a first-in-human study, IL-18 secreting autologous anti-CD19 CAR-T cells (huCART19-IL18) exhibit controllable toxic characteristics and satisfactory efficacy in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR-T cell therapy [103]. Here, IL18 is linked to non-Hodgkin lymphoma.